FDA-approved selective RET inhibitors, pralsetinib and selpercatinib, are indicated for metastatic RET fusion-positive NSCLC and medullary thyroid cancer, with selpercatinib additionally approved for other advanced RET fusion-positive solid tumors.196,197 However, the multicancer indication for selpercatinib was based on a phase I/II trial excluding HCC patients.190 Although lacking preclinical and clinical data in HCC, the success in thyroid and lung cancers prompts exploration of RET inhibitor efficacy in HCC, necessitating patient selection criteria. This evidence concerns the gene RET and hepatocellular carcinoma.